ATE219363T1 - Lösliche prodrugs von paclitaxel - Google Patents
Lösliche prodrugs von paclitaxelInfo
- Publication number
- ATE219363T1 ATE219363T1 AT97932226T AT97932226T ATE219363T1 AT E219363 T1 ATE219363 T1 AT E219363T1 AT 97932226 T AT97932226 T AT 97932226T AT 97932226 T AT97932226 T AT 97932226T AT E219363 T1 ATE219363 T1 AT E219363T1
- Authority
- AT
- Austria
- Prior art keywords
- paclitaxel
- onium salts
- methods
- novel
- salts
- Prior art date
Links
- 229930012538 Paclitaxel Natural products 0.000 title abstract 5
- 229960001592 paclitaxel Drugs 0.000 title abstract 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 5
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1997/010746 WO1998058927A1 (en) | 1997-06-20 | 1997-06-20 | Soluble prodrugs of paclitaxel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE219363T1 true ATE219363T1 (de) | 2002-07-15 |
Family
ID=22261122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97932226T ATE219363T1 (de) | 1997-06-20 | 1997-06-20 | Lösliche prodrugs von paclitaxel |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1001769B1 (de) |
| JP (1) | JP2002505682A (de) |
| AT (1) | ATE219363T1 (de) |
| AU (1) | AU3574097A (de) |
| CA (1) | CA2294606A1 (de) |
| DE (1) | DE69713526D1 (de) |
| HU (1) | HUP0002521A3 (de) |
| IL (1) | IL133585A0 (de) |
| SK (1) | SK182599A3 (de) |
| WO (1) | WO1998058927A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1171118A2 (de) * | 1999-04-09 | 2002-01-16 | Jessie L.S. Au | Verfahren und arzneimittel zur erhöhung der wirkstoffverabreichung an gewebe |
| US6541508B2 (en) | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| US6380405B1 (en) | 1999-09-13 | 2002-04-30 | Nobex Corporation | Taxane prodrugs |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
| US7115565B2 (en) | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2434641A1 (en) * | 2001-01-18 | 2002-08-22 | Pharmacia And Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
| AU2004222306A1 (en) | 2003-03-17 | 2004-09-30 | Albany Molecular Research, Inc. | Novel cyclosporins |
| EP1633317A4 (de) | 2003-05-16 | 2008-08-20 | Intermune Inc | Synthetische chemokin-rezeptor-liganden und anwendungsverfahren dafür |
| WO2005040758A2 (en) | 2003-10-24 | 2005-05-06 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
| US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
| JP2008514702A (ja) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | 新規シクロスポリン類似体およびそれらの薬学的使用 |
| WO2006039163A2 (en) | 2004-09-29 | 2006-04-13 | Amr Technology, Inc. | Cyclosporin alkyne analogues and their pharmaceutical uses |
| WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| WO2006089209A2 (en) | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby |
| JP5523313B2 (ja) | 2007-07-03 | 2014-06-18 | チルドレンズ ホスピタル アンド リサーチ センター アット オークランド | ポリシアル酸誘導体、製造方法、ならびにがん抗原産生の増強およびターゲティングにおける使用 |
| EP2296645B1 (de) | 2008-05-22 | 2014-11-19 | Galera Therapeutics, LLC | Antitumorale kombinationstherapie |
| US20110172293A1 (en) | 2008-07-08 | 2011-07-14 | Fish Jason E | Methods and Compositions for Modulating Angiogenesis |
| JP2014514300A (ja) * | 2011-04-08 | 2014-06-19 | スファエラ ファーマ ピーティーイー リミテッド | 置換メチルホルミル試薬並びに化合物の物理化学的性質及び／又は薬物動態学的性質を改質するためのそれらの使用方法 |
| WO2014014821A1 (en) | 2012-07-19 | 2014-01-23 | Redwood Biosciences, Inc. | Antibody specific for cd22 and methods of use thereof |
| EP2916835A4 (de) | 2012-11-12 | 2016-07-27 | Redwood Bioscience Inc | Verbindungen und verfahren zur herstellung eines konjugats |
| PT3613439T (pt) | 2013-02-15 | 2021-05-12 | Univ California | Recetor de antigénio quimérico e métodos de utilização do mesmo |
| KR20150135332A (ko) | 2013-03-14 | 2015-12-02 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법 |
| CA3178867A1 (en) | 2013-11-27 | 2015-06-04 | Redwood Bioscience, Inc. | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate |
| ES2833157T3 (es) | 2014-02-19 | 2021-06-14 | Aviv Therapeutics Inc | Amidas políciclicas de unión a aldehído deshidrogenasa 2 mitocondrial (aldh2) y su uso para el tratamiento del cáncer |
| WO2017083637A1 (en) | 2015-11-12 | 2017-05-18 | The Board Of Trustees Of The Leland Stanford Junior University | Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| EP3231421A1 (de) | 2016-04-11 | 2017-10-18 | Greenaltech, S.L. | Verwendungen eines carotenoids bei der behandlung oder prävention von durch stress verursachten störungen |
| CN109071634A (zh) | 2016-04-26 | 2018-12-21 | R.P.谢勒技术有限责任公司 | 抗体偶联物及其制备和使用方法 |
| WO2018017190A2 (en) | 2016-06-01 | 2018-01-25 | Baxalta Incorporated | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| US12187801B2 (en) | 2017-01-18 | 2025-01-07 | Exuma Biotech Corp. | Chimeric antigen receptors against AXL or ROR2 and methods of use thereof |
| EP3388082A1 (de) | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Kombinationskrebsimmuntherapie mit makrocyclischem pentaaza-ringkomplex |
| EP3630189A4 (de) | 2017-05-24 | 2021-06-23 | The Board of Regents of The University of Texas System | Linker für antikörper-arzneimittelkonjugate |
| MX2020008028A (es) | 2018-01-31 | 2020-12-11 | Galera Labs Llc | Terapia de combinacion para cancer con complejo de anillo macrociclico de pentaaza y agente anticancer basado en platino. |
| EP3773633A4 (de) | 2018-04-06 | 2022-01-26 | The Regents of The University of California | Verfahren zur behandlung von glioblastomen |
| AU2019249215B2 (en) | 2018-04-06 | 2026-02-19 | The Regents Of The University Of California | Methods of treating EGFRvIII expressing glioblastomas |
| CA3096838A1 (en) | 2018-04-11 | 2019-10-17 | Ohio State Innovation Foundation | Methods and compositions for sustained release microparticles for ocular drug delivery |
| WO2020018700A1 (en) | 2018-07-18 | 2020-01-23 | Manzanita Pharmaceuticals, Inc. | Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof |
| BR112021019701A2 (pt) | 2019-04-02 | 2021-12-14 | Kenjockety Biotechnology Inc | Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos |
| JP7815595B2 (ja) | 2020-01-29 | 2026-02-18 | ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 | 抗ｍｄｒ１抗体およびその使用 |
| WO2021247426A1 (en) | 2020-06-04 | 2021-12-09 | Kenjockety Biotechnology, Inc. | Anti-abcg2 antibodies and uses thereof |
| CN116529267A (zh) | 2020-06-04 | 2023-08-01 | 肯乔克蒂生物技术股份有限公司 | Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法 |
| JP7747741B2 (ja) | 2020-09-02 | 2025-10-01 | ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 | 抗ａｂｃｃ１抗体及びその使用 |
| CA3203652A1 (en) | 2020-11-13 | 2022-05-19 | William Robert ARATHOON | Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof |
| EP4247829A1 (de) | 2020-11-20 | 2023-09-27 | R.P. Scherer Technologies, LLC | Glycosid-dualspaltlinker für antikörper-wirkstoff-konjugate |
| US20250051471A1 (en) | 2021-12-13 | 2025-02-13 | William Robert Arathoon Living Trust Dated August 29, 2016 | Anti-Abcb1 Antibodies |
| WO2023159220A1 (en) | 2022-02-18 | 2023-08-24 | Kenjockety Biotechnology, Inc. | Anti-cd47 antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4013595A (en) * | 1995-10-27 | 1997-05-15 | Scripps Research Institute, The | Method for treating cancer using taxoid onium salt prodrugs |
| DK0994706T3 (da) * | 1997-05-27 | 2006-03-06 | Ivax Research Inc | Præparater til oral indgivelse af taxaner og anvendelse deraf |
-
1997
- 1997-06-20 CA CA002294606A patent/CA2294606A1/en not_active Abandoned
- 1997-06-20 AU AU35740/97A patent/AU3574097A/en not_active Abandoned
- 1997-06-20 WO PCT/US1997/010746 patent/WO1998058927A1/en not_active Ceased
- 1997-06-20 EP EP97932226A patent/EP1001769B1/de not_active Expired - Lifetime
- 1997-06-20 SK SK1825-99A patent/SK182599A3/sk unknown
- 1997-06-20 IL IL13358597A patent/IL133585A0/xx unknown
- 1997-06-20 JP JP50434699A patent/JP2002505682A/ja not_active Ceased
- 1997-06-20 DE DE69713526T patent/DE69713526D1/de not_active Expired - Lifetime
- 1997-06-20 HU HU0002521A patent/HUP0002521A3/hu unknown
- 1997-06-20 AT AT97932226T patent/ATE219363T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1001769A1 (de) | 2000-05-24 |
| SK182599A3 (en) | 2000-07-11 |
| JP2002505682A (ja) | 2002-02-19 |
| EP1001769A4 (de) | 2000-05-24 |
| DE69713526D1 (de) | 2002-07-25 |
| HUP0002521A3 (en) | 2002-04-29 |
| CA2294606A1 (en) | 1998-12-30 |
| AU3574097A (en) | 1999-01-04 |
| IL133585A0 (en) | 2001-04-30 |
| HUP0002521A2 (hu) | 2001-06-28 |
| WO1998058927A1 (en) | 1998-12-30 |
| EP1001769B1 (de) | 2002-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| DK0975595T3 (da) | Kokainanaloger | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| BR9813373A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente | |
| DE50102490D1 (de) | Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| ES2165969T3 (es) | Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios. | |
| CY1107391T1 (el) | Αρυλσυμπυκνωμενες αζαπολυκυκλικες ενωσεις | |
| DE69324466D1 (de) | L-dopa Ester-enthaltende Zusammensetzung | |
| UA41446C2 (uk) | Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі | |
| TR200101163T2 (tr) | Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları | |
| ZA848541B (en) | A kit or device and method for administering gangliosides and derivatives thereof by inhalation and pharmaceutical compositions suitable therefor | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| TR199801614T2 (xx) | Peptit t�revleri | |
| ES8400742A1 (es) | Procedimiento de preparacion de las dibenzooxepinas sustituidas y de sus sales de adicion con un acido mineral u organi-co. | |
| ATE161725T1 (de) | Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| YU17999A (sh) | Novi derivati pentaeritrita, njihova izrada i primena kao i međuproizvodi za njihovu sintezu | |
| YU25202A (sh) | Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera | |
| ATE275953T1 (de) | 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis | |
| MY126998A (en) | Substituted pyrroles. | |
| BR0016646A (pt) | Método para tratar um paciente que sofre de dor, e, composição farmacêutica | |
| BR9714774A (pt) | Pró-drogas solúveis de paclitaxel | |
| NO996311L (no) | Loeselige forlegemidler av paklitaksel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |